We are thrilled to announce that Kimialys has been included in Challenges’ prestigious “Top 100 Startups Where to Invest” list for 2023.
This recognition highlights our team’s dedication to advance innovative diagnostic tests and support pharmaceutical companies in their drug development efforts.
This achievement sets Kimialys as as one of the most promising startups in its field, meeting the needs of the fast-growing in vitro diagnostic and biopharmaceutical industries.
For further information and to see the 3 minute pitch of our CEO, Cyril Gilbert:
Challenges is a renowned French web journal and magazine that offers comprehensive coverage on various topics, including business, economy, politics, and society. It is widely recognized as a leading business publication and features a dedicated section focused on startups. This section serves as a platform to showcase innovative and promising companies across diverse industries, including the healthcare sector. It provides valuable insights into the dynamic startup ecosystem, highlighting disruptive technologies and investment opportunities in cutting-edge life science and deeptech companies.